Guggenheim Capital LLC Sells 4,547 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Guggenheim Capital LLC has reduced its position in Regeneron Pharmaceuticals by 12.1%, selling 4,547 shares and bringing its total holdings to 33,066 shares, worth approximately $20.97 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, significantly beating analysts' expectations, with a revenue of $3.68 billion, up 3.6% compared to the previous year.
• The company declared a quarterly dividend of $0.88, which reflects a 0.6% yield, alongside a dividend payout ratio of 8.87% as of the latest filing.

Guggenheim Capital LLC cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,066 shares of the biopharmaceutical company's stock after selling 4,547 shares during the period. Guggenheim Capital LLC's holdings in Regeneron Pharmaceuticals were worth $20,971,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Tompkins Financial Corp purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $32,000. Finally, Curat Global LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $32,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 2.7%

REGN opened at $587.65 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock's fifty day moving average is $553.05 and its two-hundred day moving average is $589.45. The company has a market capitalization of $62.28 billion, a P/E ratio of 14.81, a PEG ratio of 1.91 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the business posted $11.56 EPS. The business's revenue was up 3.6% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.